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Abstract: Protein tyrosine phosphatase receptor type γ (PTPRG) is a tumor suppressor gene,
down-regulated in Chronic Myeloid Leukemia (CML) cells by the hypermethylation of its promoter
region. β-catenin (CTNNB1) is a critical regulator of Leukemic Stem Cells (LSC) maintenance and
CML proliferation. This study aims to demonstrate the antagonistic regulation between β-catenin
and PTPRG in CML cells. The specific inhibition of PTPRG increases the activation state of BCR-ABL1
and modulates the expression of the BCR-ABL1- downstream gene β-Catenin. PTPRG was found
to be capable of dephosphorylating β-catenin, eventually causing its cytosolic destabilization and
degradation in cells expressing PTPRG. Furthermore, we demonstrated that the increased expression
of β-catenin in PTPRG-negative CML cell lines correlates with DNA (cytosine-5)-methyl transferase 1
(DNMT1) over-expression, which is responsible for PTPRG promoter hypermethylation, while its
inhibition or down-regulation correlates with PTPRG re-expression. We finally confirmed the role of
PTPRG in regulating BCR-ABL1 and β-catenin phosphorylation in primary human CML samples.
We describe here, for the first time, the existence of a regulative loop occurring between PTPRG and
β-catenin, whose reciprocal imbalance affects the proliferation kinetics of CML cells.
Keywords: β-catenin; PTPRG; chronic myeloid leukemia; methylation; tumor suppressor; tyrosine
phosphatase; DNMT; 5-azacytidine
1. Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disease affecting approximately 1 per
200,000 persons per year in industrialized countries. Many treatment improvements have been achieved
recently, especially in the development of new drugs, but a mortality rate of 2%–3% per year remains [1].
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A distinctive feature of CML is the reciprocal translocation, originating in hematopoietic stem cells
(HSCs), between the long arms of chromosomes 9 and 22, i.e., t (9;22) (q34;q11). This genomic aberration
generates a new fusion gene, BCR-ABL1, which encodes for a tyrosine kinase held accountable for
the neoplastic transformation of these cells by affecting normal cellular pathways essential for tissue
homeostasis, and thus causing the alteration of crucial cellular processes, such as apoptosis, cell cycle
and autophagy [2,3].
In this context, one primary goal of the research is to identify the regulatory mechanisms
antagonizing the kinase activity of BCR-ABL1 and, possibly, of other vital effectors intersecting
this pathway, as players other than BCR-ABL1 have been involved in the pathogenesis of the
disease [4]. Protein tyrosine phosphatase receptor type γ (PTPRG) is a member of the protein tyrosine
phosphatase (PTP) family, featuring an extracellular and a single transmembrane region and two tandem
intracytoplasmic catalytic domains [5]. PTPRG is widely expressed in human tissues [6] and is involved
in the regulation of cell growth, differentiation, mitotic cycle, and oncogenic transformation [7,8].
The gene encoding for this phosphatase is located in a chromosomal region (3p21-p14), frequently
deleted in renal cell and lung carcinoma, where PTPRG acts as a tumor suppressor [9–11]. Epigenetic
events, such as hyper-methylation of its promoter region, negatively regulates the transcription of
PTPRG, as demonstrated in CML and childhood acute lymphoblastic leukemia [12,13] Re-expression of
this protein occurs in the leukocytes of CML patients following targeted therapy [12]. Once activated,
PTPRG can reduce the phosphorylation level of BCR-ABL1 and some of its key targets, such as CRK-L
and STAT5 [12]. β-catenin (CTNNB1), the most critical nuclear effector of Wnt signaling, is an essential
component of cadherin-based adherents junctions. The cellular levels of β-catenin are regulated by its
phosphorylation and consequent binding to the destruction complex, including APC, Axin1, glycogen
synthase kinase-3 (GSK3β) and casein kinase I (CKI) [13–15]. Once stabilized, β-catenin moves to the
nucleus and binds TCF4/LEF (T-cell factor/lymphoid enhancer factor) transcription factors, thereby
promoting the transcription of genes involved in neoplastic transformation, such as MYC, Cyclin
D1 (CCND1) and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) [16]. This methyltransferase,
with a preference for hemimethylated sites, causes the down-regulation of different tumor suppressor
genes [17]. BCR-ABL1 phosphorylates β-catenin on Tyrosine 654, thus increasing its stability and
nuclear translocation. Imatinib mesylate (IM), a specific inhibitor of BCR-ABL1 activity, causes a
decrement of β-catenin expression, both in established cell lines and in primary cells derived from
CML patients in blast crisis [18]. We found that, in CML cells, higher expression of PTPRG correlates
with dephosphorylation and increased β-catenin-degradation. Moreover, we demonstrated that they
are part of the same molecular complex. At the same time, β-catenin promotes DNMT1 transcription,
causing PTPRG silencing through the hypermethylation of its promoter region, thus indicating a
pivotal role in the BCR-ABL1 activated pathway.
2. Results
2.1. PTPRG Regulates the Expression of β-catenin through Its Tyrosine Dephosphorylation
K562 cells were stably transfected with PTPRG cDNA (K562γ1), to restore the expression of PTPRG
in this CML cell line (Figure 1A). We also subcloned LAMA-84 (another CML cell line) cells and isolated
high and low PTPRG-expressing clones, as demonstrated by qRT-PCR and immunoprecipitation
experiments (Figure 1B). We analyzed the expression of total and tyrosine-phosphorylated BCR-ABL1
and β-catenin proteins in K562 cells expressing or not PTPRG (Figure 1C) and in both LAMA-84
clones (Figure 1D), after the treatment with a PTPRG inhibitor (PTPRG IN) [19] at a concentration
of 2 and 10 µM. We demonstrated that, in PTPRG-positive cells, the inhibition of PTPRG leads to
the BCR-ABL1 Y245 and β-catenin Y654 phosphorylation increment, in tandem with a raised level
of total protein (Figure 1C,D,F,G). Opposingly, PTPRG-negative cells were not responding to the
treatment with PTPRG IN, in terms of the effect on phosphorylation or total expression levels for these
two proteins: they remain highly-expressed at levels comparable to K562 γ1 after the inhibition of
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PTPRG. We confirmed that inhibition of BCR-ABL1 activity following treatment with imatinib mesylate
in K562 cells causes the dephosphorylation of β-catenin Y654 and consequent protein degradation,
as demonstrated by Gambacorti-Passerini’s group in 2008 [18]. The interference with BCR-ABL1
activity by PTPRG is further supported by the finding that, in K562 γ1 cells, β-catenin and its Y654
phosphorylated form are strongly reduced in comparison with the mock control clone, making the
evaluation of relative phosphorylation level challenging to assess (Figure 1E). According to the data
described above, the knock-down of PTPRG through RNA interference in unfractionated LAMA-84
cells (Figure 1H) resulted in an evident increase of phospho- and total- β-Catenin, as demonstrated by
Western blotting and immunofluorescence experiments (Figure 1I,J).
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Figure 1. β-catenin expression and phosphorylation in K562 and LAMA-84 cell lines. (A) K562 cells
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were stably transfected with an empty vector pCR 3.1 (K562 mock) or with pCR 3.1 Protein tyrosine
phosphatase receptor type γ (PTPRG) (K562 γ1) vector, containing the sequence of full-length PTPRG
(PTPRG FL). qRT-PCR and Western Blotting show the fold change expression of PTPRG relative to
K562 mock in transfected K562 cells. (B) Two clones from LAMA-84 cells, expressing alternatively low
and high PTPRG levels, were selected and screened by qRT-PCR. Additionally, immunoprecipitation,
combined with Western blotting analysis, confirmed PTPRG protein expression in these clones.
(C) Inhibition of PTPRG correlates with BCR-ABL1 tyrosine phosphorylation enhancement, and restored
expression of total and phospho-β-catenin in K562 cells transfected with PTPRG FL. As expected, there
was no response to the PTPRG inhibitor (two hours-treatment) in K562 transfected with the empty
vector. (D) LAMA-84 clones expressing low or high PTPRG protein were treated with PTPRG IN for
two hours. As anticipated, loss of PTPRG activity is associated with restored tyrosine phosphorylation
and total β-catenin expression, only in the high expressing clone. (E) PTPRG-positive and negative
K562 cells were treated with a specific inhibitor of BCR-ABL1, imatinib mesylate (IM), at 5 µM
concentration for two hours. We observed, especially in combination with PTPRG transfection, marked
dephosphorylation of β-catenin in parallel with its degradation. (F–G) Histograms representing
densitometric quantification of Western blot signals from Figure 1C,D performed using ImageJ
(U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997–2018).
Only the two high-PTPRG conditions are statistically significant. (H–I) PTPRG down-regulation
by RNA interference, through a specific siRNA (siPTPRG), as assessed by qRT-PCR and Western
blot, and expressed as fold of increase. PTPRG down-regulation by siRNA is associated with the
up-regulation of total and pY654β-catenin. The lack of signal in the line corresponding to total β-catenin
is due to the different affinity of the individual antibodies (including secondary antibodies). The result
is further confirmed by immunofluorescence analysis shown in figure (J) both pY654 β-catenin and total
β-catenin protein (red) are increased in PTPRG (green) silenced cells. The scale bar length represents
10 or 20 µm. Down-regulation of PTPRG through transfection of specific siRNA in unfractionated
LAMA-84 restores the detectable quantity of phospho- and total β-catenin. Pictures are representative
of at least three experiments. Fold of increase in the graphics is the mean values of 3 biological replicates.
p-value < 0.05 was considered statistically significant. Annotations for * p-value < 0.05, ** p-value < 0.01,
*** p-value < 0.001, and **** p-value < 0.0001 are provided accordingly. Error bars indicate the SD for
the three replicates.
In summary, in PTPRG-positive leukemic cells, the activity of this phosphatase causes the decrease
of BCR-ABL1 and β-catenin tyrosine phosphorylation and the resulting degradation of the latter.
2.2. β-catenin and PTPRG Belong to the Same Protein Complex
Previous studies reported that BCR-ABL1 increasesβ-catenin stability through its phosphorylation
activity in CML cells [18]. It can thus reasonably be expected that BCR-ABL1, β-catenin, and PTPRG
belong to the same protein complex. So, we first evaluated the presence of β-catenin and PTPRG in a
multi-molecular complex, by performing pull-down assay experiments. As a “bait” protein, we used
the inactivated PTPRG substrate-trapping mutant (D1028A) [12] recombinant protein immobilized on
nickel-agarose beads and challenged with protein extracts from K562 (BCR-ABL1 positive) and U937
(BCR-ABL1 negative) cell lines. This approach detects trapping of the substrate into the PTP catalytic
pocket [20] and has allowed us to evaluate whether an interaction between PTPRG and β-catenin
occurs. Co-precipitation happened in both cell lines, suggesting that this interaction does not require
the expression of the oncogene BCR-ABL1 (Figure 2A). Co-immunoprecipitation experiments in cells
in vivo expressing the substrate trapping form of PTPRG (K562 D1028A) confirm that β-catenin also
binds PTPRG in a fully native condition (Figure 2B).
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Figure 2. PTPRG regulates β-catenin degradation and belongs to the same protein complex. (A) Purified
PTPRG substrate-trapping mutant, termed TAT-PTPRG ICD (intracellular domain) D1028A, includes
alanine instead of aspartic acid in position 1028 that blocks phosphatase catalysis and, consequently,
traps the substrate in its catalytic pocket. TAT-eGFP (enhanced Green Fluorescent Protein) was used
as a negative control. β-catenin is detectable in K562 and U937 (respectively, BCR-ABL1-positive and
-negative cells), indicating that β-catenin and PTPRG belong to the same protein complex, regardless
of the presence of BCR-ABL1. (B) Co-immunoprecipitation analysis in K562 cells expressing inactive
mutant PTPRG D1028A (able to bind the substrate, but not dephosphorylate it) shows that PTPRG binds
β-catenin. Rabbit IgG are employed as a negative control. (C) Co-immunoprecipitation performed using
an antibody against β-catenin, followed by Western Blotting with anti-Axin1 antibody, established the
binding between these two proteins in PTPRG-positive K562 cells. (D) In the presence of PTPRG, Axin 1 is
expressed at significantly higher levels. K562 cells transfected with PTPRG FL show a strong up-regulation
of Axin1, in parallel with β-catenin down-regulation. (E) β-catenin proteolysis was blocked in K562 cells
with an inhibitor of proteasome 26S subunit, MG-132, at the concentration of 10µM, for two hours. Despite
restored expression of total β-catenin, the Y654 phosphorylation level remains lower in the presence
of PTPRG, compared with cells transfected with the empty vector. Additionally, the FOI histogram
represents the ratio of phospho β-catenin to total β-catenin. Densitometric analysis were performed
using ImageJ (U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/,
1997–2018). Annotations for ** p-value < 0.01, *** p-value < 0.001, and **** p-value < 0.0001 are provided
accordingly. (F) The combined treatment with the proteasome inhibitor MG-132 and PTPRG IN, for
two hours, gives further evidence that PTPRG has a role in β-catenin tyrosine dephosphorylation
in PTPRG-expressing LAMA-84: after blocking of β-catenin proteolysis, its phosphorylation level
increases with the inhibition of PTPRG phosphatase activity. Pictures are representative of a minimum
of three experiments.
2.3. PTPRG Expression Increases β-catenin Affinity Binding to Its Degradation Complex
The loss of β-catenin Y654 phosphorylation by BCR-ABL1 leads to the binding between β-catenin,
and its multi-protein “destruction complex”, that includes the tumor suppressors Axin1 [21] Axin1
carries binding sites for CK1 and GSK-3β and coordinates the whole phosphorylation events, involving
β-catenin proteolysis by the 26S degradation machinery and acts as a tumor suppressor in hepatocellular
carcinoma [21,22]. Immunoprecipitation experiments determined that, in K562 cells, β-catenin is
present in a complex with Axin1 only in the presence of PTPRG (Figure 2C). Besides, the restored
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expression of PTPRG in the K562 cell line (K562 γ1) induces a strong up-regulation of Axin1, along
with the down-regulation of β-catenin, compared to PTPRG-negative K562 (K562 mock) (Figure 2D).
As the additional confirmation of β-catenin-proteolysis events driven by PTPRG, we inhibited
β-catenin degradation using the proteasome 26S subunit inhibitor, MG-132, in K562 cells expressing,
or not, PTPRG. The proteasome inhibitor blocked the degradation of the protein, but dephosphorylation
still occurred in the presence of active PTPRG (Figure 2E), indeed suggesting that PTPRG
dephosphorylates β-catenin. To further strengthen this finding, we treated the unfractionated
PTPRG-positive LAMA-84 for two hours with the proteasome inhibitor MG-132 (10 µM) alone,
and with the two inhibitors PTPRG IN (10 µM) and MG-132 (10 µM) combined, respectively. In keeping
with the proposed mechanism, restored expression of the total β-catenin protein was associated with
an increased level of Y654 phosphorylation in the sample treated with both inhibitors. Conversely,
the blocking of the 26S proteasome without the inhibition of the phosphatase PTPRG prevents the
degradation of the total protein but does not increase its phosphorylation level (Figure 2F). In other
words, the lowering of Y654 phosphorylation levels is not the result of β-catenin degradation, but of
PTPRG activity driving β-catenin degradation.
2.4. PTPRG Down-Regulates β-catenin and Affects the Expression of Its Transcriptional Targets
We next evaluated whether β-catenin transcriptional targets were vicariously affected by PTPRG
expression in leukemic cells, as should be expected by the previous findings.
TCF4/β-catenin complex is known to inhibit the transcription of the p21/WAF1 gene [23]. In keeping
with this observation, we noticed that the higher expression of PTPRG is closely related to the reduced
expression of β-catenin and consequent overexpression of p21/WAF1 in K562 cells (Figure 3A), while the
contrary was observed when PTPRG is down-regulated by a specific siRNA (siPTPRG) in LAMA-84 cells
(Figure 3B). Similarly, the up-regulation of PTPRG is also associated with the decreased transcription
of two genes positively regulated by β-catenin and involved in cellular proliferation: MYC [24],
and β-catenin itself, which acts as a co-transcription factor (with TCF4/LEF) on its promoter [25]
(Figure 3A). Opposite results were obtained when PTPRG is down-regulated in the PTPRG positive
CML cell line (LAMA-84), further confirming the finding (Figure 3B).
Differently from what was expected, the regulation of the Cyclin D1 gene, positively regulated by
β-catenin, in our experimental conditions was not inversely related to PTPRG expression. The boost
of Cyclin D1 expression is likely to be offset by the up-regulation of p21/WAF1, both at mRNA and
protein levels (Figure 3A–C), thus avoiding an unchecked activation of the cell cycle. Moreover, we
demonstrated by Western blotting that, despite the fact that PTPRG increases the expression of Cyclin
D1 mRNA, the protein is mostly localized in the cytosolic compartment in PTPRG positive K562 cells
(Figure 3C), thus preventing its activity as a cell cycle inducer in the nucleus.
Given these premises, we anticipate that PTPRG inactivation by PTPRG IN should have a positive
impact on CML cell proliferation. To test this hypothesis, we performed dose-response experiments
and evaluated the extent of BCR-ABL1 protein expression and Y245 phosphorylation. As expected,
there is a dose-dependent increase of colony size and volume (Figure 3D,E), that correlates with
the enhancement of Y245 phosphorylation (Figure 3F), thus confirming and extending our previous
observation on PTPRG involvement in the regulation of CML cell proliferation [12]. Interestingly,
the samples that showed the highest number and size of colonies (treatment with 0.1 and 0.2 µM PTPRG
IN) were the same ones that expressed the highest level of phospho-BCR-ABL1, as demonstrated by
Western blotting (Figure 3F).
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Figure 3. PTPRG slows down CML cell proliferation affectingβ-catenin transcriptional targets. (A and B)
Modulation of PTPRG expression, by transfection in K562 cells or by RNA interference in LAMA-84
cells, affects β-catenin transcriptional targets, i.e., down-regulation of p21/WAF1 and up-regulation
of β-catenin and MYC, as demonstrated by qRT-PCR experiments. Surprisingly, PTPRG expression
positively correlates with the expression of Cyclin D1 mRNA, as demonstrated by qRT-PCR made after
PTPRG modulation, both in K562 and unfractionated LAMA-84 cells. (C) Western Blotting shows the
accumulation of Cyclin D1 in the cytosolic compartment for K562 transfected with PTPRG FL, suggesting
that in these cells, Cyclin D1 does not affect cell cycle progression. Moreover, the up-regulation of
p21/WAF1 in the presence of PTPRG occurs both at mRNA (Figure 3A) and protein level (this panel).
Lamin A/C and Tubulin proteins were used as nuclear and cytosolic markers, respectively. (D,E)
Unfractionated LAMA-84 cells treated with PTPRG IN (8 days with the indicated doses) showed higher
clonogenic and proliferative capability, with significant differences in size and number of colonies
grown in methocult media. (F) Western Blotting analysis depicts the BCR-ABL1 Y245 phosphorylation
level after treatment with PTPRG IN with the indicated doses. Pictures are representative of at least
three experiments. Fold of Increase in the graphics is the mean values of 3 biological replicates. p-value
< 0.05 was considered statistically significant. Annotations for * p-value < 0.05, ** p-value < 0.01,
and *** p-value < 0.001 are provided accordingly. Error bars indicate the SD for the three replicates.
2.5. β-catenin Transcriptional Activity Correlates with DNMT1 Expression
Since we have previously demonstrated that PTPRG expression is linked to the promoter
methylation levels [12], we hypothesize that DNMT proteins might negatively affect the
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transcription of this phosphatase. We focused on DNA (cytosine-5)-methyltransferase 1 (DNMT1),
a DNA-binding enzyme responsible for the down-regulation of many tumor suppressor genes through
hypermethylation of their promoter regions and a downstream effector of APC/β-catenin/TCF4
signaling [26]. It has been reported that the inhibition of β-catenin/TCF4 transcriptional activity,
through the N-terminal deletion dominant-negative mutant, decreases DNMT1 mRNA levels [17].
Interestingly, DNMT1 transcript inversely correlates with PTPRG expression, as shown by the
differential expression level in K562, LAMA84, and PTPRG-silenced LAMA84 (Figure 4A,B). Moreover,
in K562 cells expressing β-catenin (K562 mock), the β-catenin signal disruptor PNU-74654, which
prevents β-catenin binding to TCF4/LEF transcriptional co-factor, leads to the down-regulation of
DNMT1 mRNA (Figure 4C).
Three active DNA methyltransferases have been identified in mammals: DNMT1, DNMT3a,
and DNMT3b. DNMT1 is considered essential for the maintenance of DNA methylation, while
DNMT3a and DNMT3b are involved in the first step of methylation [26]. We detected, by Western
blotting, the higher expression of DNMT1 and DNMT3b in PTPRG-negative K562 cells compared to
PTPRG expressing LAMA-84 cells, while DNMT3a, considered as a tumor suppressor in hematological
malignancies [27], followed an opposite trend of expression, being present only in LAMA-84 cells
(Figure 4D).
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Figure 4. DNA (cytosine-5)-methyltransferase 1 (DNMT1) is involved in the control of PTPRG
transcription. The expression of DNMT1 mRNA correlates with β-catenin activity in CML
cells. (A) qRT-PCR showed higher expression of DNMT1 in K562 as compared to the LAMA-84.
(B) Conversely, PTPRG down-regulation by a specific siRNA (siPTPRG) in LAMA-84 cells enhances
DNMT1 levels. The control is LAMA-84 transfected with a scrambled siRNA sequence (siCTRL).
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(C) The treatment with β-catenin inhibitor PNU-74654 (20 µM concentration for 12 hours) results in a
significant decrease of DNMT1 expression. (D) DNA-methyltransferase protein expression in CML cells:
DNMT1 and DNMT3b, which cooperate for silencing a number of tumor suppressor genes in many
cancer types, are up-regulated in PTPRG-negative cells. (E) Chromatin immunoprecipitation made in
K562 cells, showing that DNMT1 binds the PTPRG promoter region, thus suggesting the contribution
of DNMT1 to PTPRG methylation-dependent silencing. GAPDH amplification confirms the specificity
of immunoprecipitation and PCR reactions. (F) Graphic representation of the methylation status of the
CpG islands inside the PTPRG promoter region after bisulfite conversion in K562 and LAMA-84 high-
and low- PTPRG clones. This technique converts unmethylated cytosines to uracil and, during PCR
amplification, they are recognized as thymines (red peaks). Methylated cytosines are unaffected by
bisulfite treatment, and, in the representative chromatograms (blue peaks), they are indicated by the
arrows. (G) Heat map representing methylation pattern of specific genomic sites inside the PTPRG
promoter region in K562, and high and low PTPRG-LAMA-84 clones. (H) qRT-PCR confirms the
down-regulation of DNMT1 mRNA in K562 cells after siRNA transfection, also in combination with
5-azacytidine(72 h-treatment), an inhibitor of DNA-methyltransferases, that inserts a fifth genomic
base, a cytosine, with an N in position 5 of pyrimidine ring that cannot be methylated. (I,J) The DNMT1
silencing through a specific siRNA against DNMT1 as well as 5-azacytidine treatment (72 h) leads to a
significative up-regulation of PTPRG mRNA in K562 cells. The combination of these two treatments
induces a 5-fold increase of PTPRG mRNA expression, that becomes detectable at the protein level.
Pictures are representative of at least three experiments. Fold of increase in the graphics is the mean
values of 3 biological replicates. p-value < 0.05 was considered statistically significant. Annotations for
* p-value < 0.05, ** p-value < 0.01, and *** p-value < 0.001 are provided accordingly. Error bars indicate
the SD for the three replicates.
2.6. DNMT1 Binds PTPRG Promoter Region and Regulates PTPRG Expression
We therefore evaluated whether DNMT1 could represent a modulator of PTPRG expression
through the regulation of its promoter methylation status. As demonstrated by previous works [28,29],
DNMT1 can bind gene promoter regions to control their transcription by methylation. Furthermore,
the PTPRG promoter region contains two distinct CpG islands available for methylation by DNMT1
and, consequently, potential binding sites for this protein.
Chromatin immunoprecipitation assay is a powerful technique suitable to map the interaction of
proteins with specific genomic regions. This assay confirmed the interaction between DNMT1 and
the CpG islands within the PTPRG promoter region (Figure 4E), indicative of a role for DNMT1 in
PTPRG down-regulation.
As further confirmation of our data, we sequenced the genomic region of the PTPRG promoter,
after bisulfite conversion of the DNA from K562 and LAMA-84 cells. The sequencing analysis revealed
a solid methylation pattern of this region only in cells with low expression of PTPRG (Figure 4F,G),
stronger in K562 cells compared with both clones (high and low-PTPRG expression) of LAMA-84.
In order to validate the involvement of DNMT1 in PTPRG transcriptional regulation, we treated
PTPRG-negative K562 cells with a specific siRNA against DNMT1, alone or in combination with
5-azacytidine, an inhibitor of DNA methyltransferases (Figure 4H). Although even a single treatment
leads to a restored expression of PTPRG, the combination of 5-azacytidine with DNMT1 siRNA caused
a 5-fold increment of PTPRG mRNA in comparison with control. Increased mRNA expression matches
with the recovery of detectable protein levels (Figure 4I,J).
2.7. PTPRG Dephosphorylates BCR-ABL1 and β-catenin in CML Primary Cells
We finally tested whether PTPRG affects BCR-ABL1 and β-catenin phosphorylation in primary
CML cells. We first evaluated by qRT-PCR (data not shown), and flow cytometry the level of PTPRG
in peripheral blood and bone marrow leukocytes obtained at the time of diagnosis from nine CML
patients (Table 1) (Figure 5A,B left panels). Five CML patients expressed detectable PTPRG levels,
while four were PTPRG-negative. We tested the phosphorylation level of BCR-ABL1 in all nine patients
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and that related to phospho β-catenin in 6 out of 9 patients. In all the patients expressing PTPRG,
10µM PTPRG IN enhanced Y245 phosphorylation of BCR-ABL1 and, consistently with our previous
results, Y654 phosphorylation of β-catenin (Figure 5A,B right panel). Interestingly, two patients
samples presenting undetectable levels of PTPRG (MFI 1.15, patient 3 and 1.03, patient 8) did not show
increased BCR-ABL1 Y245 phosphorylation in response to PTPRG IN (Figure 5A–D). These results fully
confirm and extend to primary cells the previous data that indicate an active role of this phosphatase
in BCR-ABL1 activation and β-catenin degradation and, consequently, the inverse correlation between
PTPRG expression and BCR-ABL1 activity in cells isolated by the peripheral blood of CML patients.
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Figure 5. PTPRG dephosphorylates BCR-ABL1 and β-catenin in Chronic Myeloid Leukemia (CML)
primary cells. (A,B) Flow cytometry analysis shows PTPRG expression in all untreated CML patients
(left panels). Total peripheral leukocytes from five PTPRG-positive patients (#ID: 1, 2, 4, 5, 6) and from
four lacking detectable levels of the phosphatase (#ID: 3, 7, 8, 9) were treated with 2 and/or 10 µM
PTPRG IN for 2 h. Enhanced Tyr245-BCR-ABL1 phosphorylation was observed by Western Blotting
analysis in cells from PTPRG-positive patients (right panel A and B), as well as Tyr654-β-catenin
phosphorylation (right panel B), thus confirming that PTPRG controls the levels of BCR-ABL1 and
β-catenin phosphorylation and function also in primary cells. (C,D) Densitometric analysis of Western
blotting signals performed using ImageJ (U. S. National Institutes of Health, Bethesda, Maryland, USA,
https://imagej.nih.gov/ij/, 1997–2018) compares the expression of pTyrBCR-ABL1 and pTyr654-β-catenin
in all patients before and after the treatment with PTPRG IN. Annotations for * p-value < 0.05,
** p-value < 0.01, and **** p-value < 0.0001 are provided accordingly. Error bars indicate the SD for the
different samples.
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Table 1. Patient characteristics.
Pat.# Age M/F PTPRG Expression (MFI Ratio) Hb (g/dL) WBC (109/L) Cytogenetics PB Blasts (%) BM Blasts (%) BCR-ABL1 SOKAL Risk
1 32 M 2.69 10.4 360.5 46,XY,t(9;22)(q34;q11) 0.61 4 b2a2 High
2 75 F 2.79 10.5 186.4 46,XX,t(9;20;22)(q34;q13.1;q11) 5.32 4.9 b3a2 High
3 37 M 1.15 13.3 69.6 46,XY,t(9;22)(q34;q11) 0.97 1 b3a2 Interm
4 39 M 2.34 14.8 42.35 46,XY,t(2;9:22)(p15;q11) 0.22 0.41 b3a2 Low
5 45 F 2.50 12.2 16.21 46,XX,t(9;22)(q34;q11) 0.15 0.11 b3a2 Low
6 65 M 6.57 15.8 33.07 46,XX,t(9;22)(q34;q11) 0.2 0.28 b2a2 Low
7 74 M 1.46 12.7 23.13 46,XX,t(9;22)(q34;q11) 0.09 0.43 b2a2 Interm
8 64 M 1.03 10.2 28.36 46,XX,t(9;22)(q34;q11) 0.03 no BM b2a2 Low
9 71 F 1.36 11.4 19.88 46,XX,t(9;22)(q34;q11) 0.25 0.94 b3a2 Interm
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3. Discussion
Our previous works demonstrated the role of tumor suppressor for PTPRG in CML [12]
and, in a different cell context, its capability to target JAK2 [30], a kinase governing pathways
of relevant therapeutic interest in CML [31]. Here, we extend these previous findings by exploring in
deeper detail the molecular mechanisms underlying the tumor-suppressive effect of this phosphatase.
We proved that PTPRG dephosphorylates the residue Y245 in the BCR-ABL1 SH2–kinase-domain
linker, essential for the full activation of this kinase and one of five high-confidence phosphorylation
sites of BCR-ABL1, with structural and functional roles [32]. Dephosphorylation, with consequent
BCR-ABL1 inactivation or weakening, represents a dramatic event for CML cells leading to increased
apoptosis and differentiation, followed by reduced proliferation and aggressiveness [33]. This evidence
is of considerable significance, thinking the role of Leukemic Stem Cells (LSC) in the resistance to
Tyrosine Kinase Inhibitors and aberrant activation of self-renewal [34]. In the last few years, many
studies have suggested the active contribution of β-catenin on LSC maintenance [35], even if the
relationship between β-catenin and BCR-ABL1 is still under investigation. Some authors described
BCR-ABL1 as a β-catenin target [36], demonstrating that β-catenin-deficient murine CML cells showed
lower BCR-ABL1 protein level and phosphorylation activity. MYC, a β-catenin-downstream gene,
controls BCR-ABL1 transcription, suggesting that BCR-ABL1 is an indirect target of β-catenin [37].
Furthermore, lncRNA-BGL3 was highly induced in response to the disruption of BCR-ABL1 expression,
or by inhibiting BCR-ABL1 kinase activity in K562 cells and leukemic cells derived from CML
patients. Conversely, BCR-ABL1 represses lncRNA-BGL3 expression through MYC-dependent DNA
methylation [38]. Moreover, BCR-ABL1 regulates β-catenin through the phosphorylation of Tyr 86 and
654 that affects the stabilization of cytosolic β-catenin and its binding with its degradation complex [18].
Altogether, these data show that β-catenin, as Wnt pathway effector, is required to maintain normal
HSC function, while the loss of this protein hampers CML progression [36]. Of note, nuclear β-catenin
is involved in intrinsic BCR-ABL1 kinase-independent TKI resistance in primary CML cells [39] and
PTPRG co-precipitates with β-catenin in enterocytes derived from transgenic mice, featuring the
loss of the wild-type Apc allele (ApcMin−/−). In tumors derived from these mice, reduced levels of
tyrosine-phosphorylated β-catenin have been reported [40].
Collectively, our data demonstrate that β-catenin degradation is controlled by PTPRG expression:
PTPRG can dephosphorylate BCR-ABL1, thus preventing β-catenin tyrosine phosphorylation and,
at the same time, apparently directly dephosphorylates β-catenin, causing the almost complete
proteolysis within two hours (Figure 6, left panel). Based on these experiments, we cannot assess
whether the dephosphorylation of β-catenin is a consequence of BCR-ABL1 inhibition mediated
by PTPRG, or the effect of a direct dephosphorylation. However, we have shown that PTPRG and
β-catenin belong to the same complex, as they co-immunoprecipitate. This phenomenon is independent
of BCR-ABL1 expression, as it occurs also in the BCR-ABL1-negative U937 cell line, strongly suggesting
a direct interaction between PTPRG and β-catenin.
The loss of β-catenin reduces its transcriptional activity, as reflected by the down-regulation of
MYC and β-catenin mRNA, in combination with p21/WAF1 mRNA up-regulation, which may explain
lower cellular proliferation rate in the presence of PTPRG.
DNA methylation is a significant epigenetic modification in mammals, and, under physiological
condition, 80% of the whole genome, not associated with promoter sequences, is methylated. On the
contrary, in cancer cells, CpG-rich promoter methylation catalyzed by DNA methyl-transferases is a
common mechanism of tumor suppressor silencing [41]. In our previous work, we demonstrated that
the PTPRG promoter is methylated and that 55% of leukocytes from CML patients treated with TKI
showed demethylation of the region and a re-expression of PTPRG [12].
DNMT1 is the major DNA-methyl-transferase responsible for the maintenance of DNA methylation
after DNA replication; by contrast, DNMT3a and DNMT3b are de novo methyl-transferases that are often
dysregulated in many types of tumors, such as colon, breast and pancreatic cancers, thus representing a
therapeutic target [26]. DNMT3a has recently emerged as one of the most important tumor suppressors
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in hematological malignancies, in particular in AML cells, featuring a high number of mutations that
are involved in resistance to some types of drugs [27].
DNMT1 and DNMT3b cooperate for tumor suppressor silencing [42], and we observed a higher
expression of these two proteins in K562 cells, as compared to PTPRG-expressing LAMA-84. Besides,
β-catenin/TCF4 transcriptional complex regulates DNMT1 expression. Indeed, it was demonstrated
that the inactive dominant-negative version of this protein complex decreases DNMT1 expression [17].
We present here a cross-talk between DNMT1 expression and PTPRG promoter methylation,
which was confirmed by the results of chromatin immunoprecipitation and by the evidence of increased
PTPRG transcription in K562 following DNMT1 down-regulation.
Figure 6. Schematic representation summarizing the regulative loop between β-catenin and PTPRG.
In low-PTPRG expressing cells, BCR-ABL1 phosphorylatesβ-catenin in Tyrosine 86 and 654 in CML cells.
This phosphorylation affects β-catenin cytosolic stabilization, blocking its binding with the destruction
complex. This condition allows β-catenin to translocate into the nucleus and act as a transcriptional
activator for many genes, including DNMT1 that is responsible for PTPRG promoter methylation
and consequent down-regulation. On the other hand, in high-PTPRG expressing cells, PTPRG
dephosphorylates BCR-ABL1, preventing β-catenin tyrosine phosphorylation; in addition, PTPRG
directly dephosphorylates β-catenin, causing its proteolysis through the binding with its degradation
complex. This condition affects the DNMT1 transcription, with the consequent down-regulation of this
methyl-transferase, and hypo-methylation of PTPRG promoter region.
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These results reveal a previously unrecognized regulative loop between β-catenin and PTPRG,
with β-catenin controlling PTPRG transcription. At the same time, through DNMT1, β-catenin
controls both BCR-ABL1 (through MYC expression) and PTPRG itself. On the other hand, PTPRG and
BCR-ABL1 regulate β-catenin levels by modulating, in opposite ways, its tyrosine phosphorylation
levels. Also, PTPRG increases the expression of Axin1, a key regulator of β-catenin degradation [15].
Of relevance is the observation that the same mechanism described in CML cell lines is
active in leukocytes from CML patients, where PTPRG inhibition results in the up-regulation
of Y245-phospho-BCR-ABL1 and Y654-phospho-β-catenin. Conversely, cells from CML patients
expressing undetectable levels of PTPRG displayed the highest levels of Y245-phospho-BCR-ABL1
and Y654-phospho-β-catenin. Of note is the fact that they were refractory to PTPRG IN treatment,
a key observation further confirming an exquisite specificity of this chemical inhibitor, utilized for the
first time in cellular models.
Altogether this study describes a novel PTPRG-dependent regulative loop involving critical
regulatory components of the BCR-ABL1 signaling pathway (Figure 6), further strengthening the role
of PTPRG as a crucial tumor suppressor in CML cells and a possible candidate for specific therapies
aimed at its re-expression or activation.
4. Materials and Methods
4.1. Cell Lines and Transfection
The CML cell lines K562 (American Type Culture Collection, Manassas, VA, USA), LAMA-84
and the human histiocytic lymphoma cell line U937 (Leibniz Institute DSMZ-German Collection of
Microorganisms and Cell Cultures GmbH, Braunschweig, Germany) were cultured in RPMI 1640
medium, supplemented with 10% Fetal Bovine Serum (FBS) and 2 mmol/L of Ultraglutamine 1-(Lonza,
Milan, Italy). Full-length human PTPRG cDNA, mutant PTPRG D1028A, or empty vector (pCR 3.1,
Thermo Fisher Scientific, Monza, Italy), used to transfect K562 cells, were previously described [12].
4.2. Inhibitors
K562 and LAMA-84 cell lines were treated with the PTPRG inhibitor (from now on named PTPRG
IN) 3-(3,4-dichlorobenzylthio) thiophene-2-carboxylic acid [19] (BIONET sold by Key Organics Ltd,
Camelford, Cornwall, UK) at 0.05 to 50 µM and with imatinib mesylate (IM) (Selleckem, Houston, TX,
USA), 1 or 5 µM, for 2 h at 37 ◦C. The proteasome 26S unit inhibitor, MG-132, (Santa Cruz Biotechnology
Inc, Heidelberg Germany) was used at 10 µM for 2 h at 37 ◦C. Moreover, 5-azacydine (MilliporeSigma,
Milan, Italy) was used at 10 µM for 72 h at 37 ◦C. PNU-74654 (MilliporeSigma, Milan, Italy) was used
at 20 µM for 12 h at 37 ◦C.
4.3. CML Patients
CML cells were collected from patients with untreated, chronic-phase disease, after informed
consent (described in Table 1). 20 × 106 cells cryopreserved in 500 µL of 90% FBS and 10% DMSO
were thawed using 4 µL of deoxyribonuclease I (260 U/µL), seeded in IMDM (Thermo Fisher Scientific,
Monza, Italy) with 20% FBS for three hours and then treated with PTPRG IN, at different concentrations
for two hours at 37 ◦C. Cells were lysed in boiling “sample buffer” (SB): 160 mM Tris, 20% glycerol, 5%
β-mercaptoethanol, 4% SDS, 0.01% bromophenol blue and subjected to Western blotting. The study
was approved by the Ethical Committee of Azienda Ospedaliera Universitaria Integrata Verona,
protocol N. 1828, 12 May 2010, “Institution of cell and tissue collection for biomedical research in
Onco-Hematology”. The study was approved by the Local Ethics Committee, AOUI Verona (Permit
Number: 25066); informed consent, in accordance with the declaration of Helsinki, was obtained from
each patient.
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4.4. Clonogenic Assay
LAMA-84 and K562 cells were resuspended in IMDM (Thermo Fisher), with 2% FBS and
0.3% NaHCO3 (MilliporeSigma, Milan, Italy), at a concentration of 16.5 × 103 or 33 × 103 cells/mL.
Then, 50 µL of this cellular dilution were mixed with Methocult (StemCell Technologies Germany
GmbH, Cologne, Germany) and PTPRG IN at different concentrations (0.005–0.1–0.2 µM) or DMSO
and transferred in 24-well plates. After 8 days, cell colonies in each well were stained with
3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (MilliporeSigma, Milan, Italy)
and, after 3 h at 37 ◦C, captured and quantified with ImageQuant®LAS 4000 colony counting module
(GE Healthcare Europe GmbH, Milan, Italy).
4.5. Small Interfering RNA (siRNA) Transfection
Small interfering RNA (siRNA) targeting PTPRG (siPTPRG, No s-11550), siRNA targeting DNMT1
(siPTPRG, No s-4215), and negative control (scrambled sequence) were purchased from Applied
Biosystems®, Thermo Fisher Scientific, Milan, Italy. PTPRG-negative K562 and LAMA-84 cells
were transfected at a concentration of 1 × 105/mL with 30 nM of siRNAs, using siPORT™ NeoFX™
Transfection Agent (Applied Biosystems®, Thermo Fisher Scientific, Milan, Italy), according to the
manufacturer’s instructions. Cells were cultured for 72 or 96 h, washed twice with cold TBS, and lysed.
4.6. RNA Isolation, Reverse Transcription, qRT–PCR
Cells (5× 106) were resuspended in 1 mL of TRIzol® reagent (Thermo Fisher Scientific, Milan, Italy)
and stored at −80 ◦C until the RNA extraction. Total RNA was isolated following the manufacturer’s
instructions and measured with the Nanodrop 2000c instrument (Thermo Fisher Scientific, Milan, Italy).
For cDNA synthesis, 2 µg of total RNA were reverse-transcribed using random hexamer primers,
with the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Milan, Italy)
10 min 25 ◦C, 120 min 37 ◦C, 5 min 85 ◦C. qRT-PCR was performed using SYBR® Green PCR Master
Mix (Thermo Fisher Scientific, Milan, Italy), 2 min 50 ◦C, 2 min 95 ◦C, 15 s 95 ◦C, 1 min 60 ◦C and
specific primers for each gene were designed with the free, open-source GUI application PerlPrimer
v1.1.21, http://perlprimer.sourceforge.net/ (Supplementary Table S1). The data were normalized with
β-Actin as internal control and expressed as fold of increase of fluorescence.
4.7. Immunoprecipitation
Specific antibodies against β-catenin (3 µg, Santa Cruz Biotechnology Inc, Heidelberg Germany)
and PTPRG [43] were added to 30 µL of Protein G-Sepharose beads (GE Healthcare Europe GmbH,
Milan, Italy) and incubated for one hour at 4◦C with gentle rocking. Then, washed beads bound to the
antibody were added to 500 µg of protein lysates and incubated again for three hours at 4 ◦C with
gentle rocking. Finally, the beads were washed, resuspended in Sample Buffer 2×, denaturated at 95 ◦C
and subject to Western blotting.
4.8. Immunofluorescence
Cells from the LAMA-84 cell line (1 × 105) treated with PTPRG siRNA or scramble sequence,
were subject to cytospin (Thermo Fisher Scientific, Milan, Italy) and immediately fixed in 4%
paraformaldehyde for 10 min at 4 ◦C. After three washing steps, slides were incubated overnight at
4 ◦C with primary antibodies: 5 µg/mL phospho-β-catenin (Tyr 654) (ECM Biosciences, Versailles, KY,
USA), 5 µg/mL total- β-catenin (Santa Cruz Biotechnology Inc, Heidelberg Germany) and 5 µg/mL
anti-PTPRG [44], in a buffer containing PBS/Tween20 0.05%/BSA 1%/NaN3 4mM, followed by the
proper secondary Alexa Fluor-conjugated antibodies (1:2000, Thermo Fisher Scientific, Milan, Italy),
for 1 h at room temperature. After mounting with an anti-fading solution, samples were analyzed by
fluorescence microscopy (DM6000B, Leica Microsystems, Wetzlar, Germay) and confocal microscopy
(TCS-SP5, Leica Microsystem, Wetzlar, Germay).
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4.9. Pull-Down Assay
Intracellular domain (ICD) of PTPRG D1028A (PTPRG inactive mutant) and enhanced green
fluorescent protein (eGFP) construct, both cloned in T7-based HisG-tagged vector expression pRSET A
(Thermo Fisher Scientific, Milan, Italy), were expressed in BL21 (DE3) pLysS Escherichia coli (Thermo
Fisher Scientific, Milan, Italy). For the pull-down assay, 3 mg of total bacterial protein lysates were
conjugated to 30 µL of HIS-Select Nickel Affinity Gel (MilliporeSigma, Milan, Italy) and incubated,
after extensive washing, with 500 µg of protein lysates from K562 and U937 cell lines for 3 h at 4 ◦C,
with gentle rocking. The beads were collected, washed twice with lysis buffer and once with cold TBS,
and then subjected to SDS-PAGE and Western blotting.
4.10. Methylation Analysis
The DNA extraction was performed using DNeasy Blood & Tissue Kit (Qiagen Sciences Inc,
Germantown, MD, USA), according to the manufacturer’s instruction. Subsequently, the DNA (2 µg)
was subjected to bisulfite conversion and purification using EpiTect™ Fast DNA Bisulfite Kit (Qiagen
Sciences Inc, Germantown, MD, USA), according to the manufacturer’s protocol. After bisulfite
conversion, the PTPRG promoter region was analyzed by PCR amplification and sequencing. PCR
reaction was made using 50× Advantage® 2 Polymerase Mix (Takara Bio USA Inc, Mountain View,
CA, USA). The PCR product was purified with ExoSAP-IT™ PCR Product Cleanup Reagent (Thermo
Fisher Scientific, Waltham, MA, USA), and subjected to Sanger sequencing. The analysis of sequencing
was performed with Sequencer 5.4.6 software (Gene Codes Corporation, Ann Arbor, MI, USA) to
evaluate the C to T conversion rate.
4.11. Western Blotting
Cells were lysed in Lysis buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 10% Glycerol and 0,5%
Nonidet P40), or in boiling Sample Buffer. Then, 10–30 µg of proteins were loaded onto 6 to 12%
polyacrylamide, 0.1% SDS gels, and electro-blotted on nitrocellulose membranes (GE Healthcare
Europe GmbH, Milan, Italy). Blocking solution was obtained using TBS-0.05% Tween®20/BSA 5% or
fat-free milk 5%. All antibodies (Supplementary Table S2) were diluted in TBS-0.05% Tween®20/BSA
or fat-free milk 1%–5%. The membranes were washed and assayed with ECL (MilliporeSigma, Milan,
Italy) after overnight incubation at 4 ◦C, three times washing with TBS-0.05% Tween®20 (TBS-T) and
incubation with appropriate HRP-conjugated secondary antibodies. All images were acquired with the
digital imaging system ImageQuant®LAS 4000 biomolecular imager (GE Healthcare Europe GmbH,
Milan, Italy).
4.12. Statistical Analysis
The data analysis was performed using GraphPad® 8.3.0 Instat software (GraphPad Software,
San Diego, CA, USA). The Student’s two-tailed unpaired t-test was applied to qRT-PCR and Colony
assay (number and volume of colonies) experiments. For qRT-PCR analysis, we considered absolute
values, even though the graphs show just the fold-change, representing the data more clearly. Also,
the student’s two-tailed unpaired t-test was applied to the densitometric comparisons depicted in
Figure 1F,G, Figure 5C,D. Each PTPRG IN condition was compared to the DMSO control. The analysis
was done separately for each different protein employing ImageJ software (U. S. National Institutes of
Health, Bethesda, MD, USA https://imagej.nih.gov/ij/, 1997–2018). Results with a p-value < 0.05 were
considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/7/2298/s1.
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